 Kathleen Packard
Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Students, Health Occupations | 2 | 2019 | 37 | 0.670 |
Why?
| | Interprofessional Relations | 2 | 2019 | 276 | 0.580 |
Why?
| | Fish Oils | 1 | 2019 | 27 | 0.570 |
Why?
| | Education, Distance | 1 | 2019 | 59 | 0.560 |
Why?
| | Cardiovascular Agents | 2 | 2016 | 166 | 0.540 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2019 | 143 | 0.540 |
Why?
| | Simulation Training | 1 | 2019 | 136 | 0.510 |
Why?
| | Medication Adherence | 3 | 2016 | 540 | 0.500 |
Why?
| | Secondary Prevention | 3 | 2016 | 251 | 0.480 |
Why?
| | Aspirin | 2 | 2016 | 406 | 0.470 |
Why?
| | Patient Safety | 1 | 2019 | 356 | 0.460 |
Why?
| | Acute Coronary Syndrome | 3 | 2014 | 297 | 0.420 |
Why?
| | Rhabdomyolysis | 1 | 2014 | 24 | 0.400 |
Why?
| | Pharmacists | 2 | 2014 | 258 | 0.360 |
Why?
| | Medication Reconciliation | 1 | 2012 | 32 | 0.350 |
Why?
| | Antipsychotic Agents | 1 | 2014 | 211 | 0.350 |
Why?
| | Coronary Artery Bypass | 3 | 2004 | 268 | 0.340 |
Why?
| | Cardiac Rehabilitation | 1 | 2012 | 46 | 0.340 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2014 | 499 | 0.340 |
Why?
| | Professional Role | 2 | 2014 | 170 | 0.340 |
Why?
| | Coronary Disease | 2 | 2004 | 382 | 0.320 |
Why?
| | Education, Pharmacy | 1 | 2010 | 120 | 0.280 |
Why?
| | Atrial Fibrillation | 4 | 2011 | 558 | 0.260 |
Why?
| | Angiotensin Receptor Antagonists | 3 | 2010 | 115 | 0.260 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2010 | 252 | 0.240 |
Why?
| | Heart Failure | 3 | 2014 | 2326 | 0.230 |
Why?
| | Patient Care Team | 1 | 2012 | 697 | 0.230 |
Why?
| | Coronary Artery Disease | 1 | 2012 | 750 | 0.220 |
Why?
| | Thrombosis | 2 | 2012 | 400 | 0.210 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2191 | 0.210 |
Why?
| | Calcium Channel Blockers | 3 | 2010 | 166 | 0.210 |
Why?
| | Losartan | 1 | 2004 | 13 | 0.210 |
Why?
| | Nail Diseases | 1 | 2004 | 9 | 0.210 |
Why?
| | Hospitalization | 2 | 2014 | 2461 | 0.210 |
Why?
| | Cholesterol, HDL | 1 | 2005 | 201 | 0.200 |
Why?
| | Graft Occlusion, Vascular | 1 | 2004 | 40 | 0.200 |
Why?
| | Angiotensin II | 1 | 2004 | 102 | 0.200 |
Why?
| | Histamine | 1 | 2003 | 52 | 0.190 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1582 | 0.190 |
Why?
| | Diltiazem | 1 | 2003 | 17 | 0.190 |
Why?
| | Gemfibrozil | 1 | 2002 | 9 | 0.190 |
Why?
| | Propanolamines | 1 | 2003 | 40 | 0.190 |
Why?
| | Fenofibrate | 1 | 2002 | 28 | 0.190 |
Why?
| | Polyuria | 1 | 2002 | 2 | 0.190 |
Why?
| | Th1 Cells | 1 | 2003 | 139 | 0.180 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2010 | 229 | 0.180 |
Why?
| | Th2 Cells | 1 | 2003 | 175 | 0.180 |
Why?
| | Catheters, Indwelling | 1 | 2003 | 96 | 0.180 |
Why?
| | Bronchial Diseases | 1 | 2002 | 38 | 0.180 |
Why?
| | Piperazines | 3 | 2014 | 375 | 0.180 |
Why?
| | Lactones | 1 | 2002 | 59 | 0.180 |
Why?
| | Hyperlipidemias | 1 | 2002 | 120 | 0.180 |
Why?
| | Edema | 1 | 2002 | 125 | 0.170 |
Why?
| | Anti-Obesity Agents | 1 | 2002 | 67 | 0.170 |
Why?
| | Constipation | 1 | 2002 | 98 | 0.170 |
Why?
| | Asthma | 2 | 2003 | 1797 | 0.160 |
Why?
| | Tissue Plasminogen Activator | 1 | 2003 | 248 | 0.160 |
Why?
| | Fibrinolytic Agents | 1 | 2003 | 297 | 0.150 |
Why?
| | Students, Pharmacy | 2 | 2012 | 96 | 0.150 |
Why?
| | Smoking Cessation | 1 | 2004 | 441 | 0.150 |
Why?
| | Nursing Evaluation Research | 1 | 2019 | 43 | 0.150 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1368 | 0.150 |
Why?
| | Nursing Education Research | 1 | 2019 | 43 | 0.150 |
Why?
| | Education, Nursing, Graduate | 1 | 2019 | 37 | 0.140 |
Why?
| | Eicosapentaenoic Acid | 1 | 2019 | 37 | 0.140 |
Why?
| | Humans | 26 | 2019 | 145783 | 0.140 |
Why?
| | Drug Interactions | 4 | 2015 | 405 | 0.140 |
Why?
| | Renal Dialysis | 1 | 2003 | 466 | 0.140 |
Why?
| | Medical Errors | 1 | 2019 | 119 | 0.140 |
Why?
| | Docosahexaenoic Acids | 1 | 2019 | 88 | 0.140 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 956 | 0.140 |
Why?
| | Students, Nursing | 1 | 2019 | 93 | 0.130 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 599 | 0.120 |
Why?
| | Smoking | 1 | 2004 | 1477 | 0.120 |
Why?
| | Perception | 1 | 2019 | 378 | 0.120 |
Why?
| | Prasugrel Hydrochloride | 2 | 2014 | 22 | 0.120 |
Why?
| | Cytokines | 1 | 2003 | 2069 | 0.110 |
Why?
| | Thiophenes | 2 | 2014 | 117 | 0.110 |
Why?
| | Pharmaceutical Services | 2 | 2014 | 76 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2002 | 920 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2019 | 584 | 0.110 |
Why?
| | Male | 13 | 2019 | 73010 | 0.100 |
Why?
| | Cardiovascular System | 1 | 2015 | 139 | 0.100 |
Why?
| | Treatment Outcome | 6 | 2016 | 11794 | 0.100 |
Why?
| | Acetanilides | 1 | 2013 | 11 | 0.100 |
Why?
| | Sodium Channel Blockers | 1 | 2013 | 23 | 0.100 |
Why?
| | Adenosine | 2 | 2014 | 255 | 0.100 |
Why?
| | Qualitative Research | 2 | 2019 | 1683 | 0.100 |
Why?
| | Antidepressive Agents | 1 | 2015 | 242 | 0.100 |
Why?
| | Angina Pectoris | 1 | 2013 | 76 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2004 | 2977 | 0.100 |
Why?
| | Female | 13 | 2019 | 79045 | 0.100 |
Why?
| | Recurrence | 1 | 2016 | 1139 | 0.100 |
Why?
| | Affect | 1 | 2015 | 321 | 0.090 |
Why?
| | Body Temperature | 1 | 2014 | 227 | 0.090 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1062 | 0.090 |
Why?
| | United States | 4 | 2019 | 16126 | 0.090 |
Why?
| | Interdisciplinary Studies | 1 | 2012 | 30 | 0.090 |
Why?
| | Risk Factors | 3 | 2016 | 10919 | 0.090 |
Why?
| | Health Resources | 1 | 2013 | 130 | 0.090 |
Why?
| | Health Occupations | 1 | 2012 | 36 | 0.090 |
Why?
| | Imines | 1 | 2012 | 6 | 0.090 |
Why?
| | Heart Diseases | 1 | 2015 | 341 | 0.090 |
Why?
| | Professional Competence | 1 | 2012 | 91 | 0.090 |
Why?
| | Aged | 8 | 2014 | 26217 | 0.090 |
Why?
| | Cardiac Surgical Procedures | 2 | 2010 | 611 | 0.080 |
Why?
| | Medication Errors | 1 | 2012 | 85 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1043 | 0.080 |
Why?
| | Hospitals, Private | 1 | 2010 | 12 | 0.080 |
Why?
| | Hemorrhage | 2 | 2014 | 822 | 0.080 |
Why?
| | Cooperative Behavior | 1 | 2012 | 463 | 0.070 |
Why?
| | Sotalol | 2 | 2010 | 13 | 0.070 |
Why?
| | Amiodarone | 2 | 2010 | 31 | 0.070 |
Why?
| | Intracranial Hemorrhages | 1 | 2009 | 106 | 0.070 |
Why?
| | California | 1 | 2010 | 473 | 0.070 |
Why?
| | Warfarin | 1 | 2009 | 179 | 0.070 |
Why?
| | Postoperative Period | 2 | 2010 | 351 | 0.060 |
Why?
| | Pyridines | 1 | 2012 | 609 | 0.060 |
Why?
| | Educational Measurement | 1 | 2010 | 326 | 0.060 |
Why?
| | Amlodipine | 1 | 2006 | 10 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 740 | 0.060 |
Why?
| | Hypertension | 2 | 2006 | 1276 | 0.060 |
Why?
| | Middle Aged | 6 | 2014 | 36309 | 0.060 |
Why?
| | Tetrazoles | 1 | 2006 | 50 | 0.060 |
Why?
| | Antihypertensive Agents | 2 | 2010 | 521 | 0.060 |
Why?
| | Valine | 1 | 2006 | 83 | 0.060 |
Why?
| | Anticoagulants | 1 | 2011 | 748 | 0.060 |
Why?
| | Depression | 1 | 2015 | 1559 | 0.060 |
Why?
| | Adult | 5 | 2014 | 40881 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2010 | 777 | 0.050 |
Why?
| | Influenza Vaccines | 1 | 2009 | 534 | 0.050 |
Why?
| | Hyperemia | 1 | 2005 | 49 | 0.050 |
Why?
| | India | 1 | 2005 | 213 | 0.050 |
Why?
| | Toes | 1 | 2004 | 16 | 0.050 |
Why?
| | Cross-Over Studies | 2 | 2006 | 610 | 0.050 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2004 | 144 | 0.050 |
Why?
| | Histamine H1 Antagonists | 1 | 2003 | 24 | 0.050 |
Why?
| | Brachial Artery | 1 | 2005 | 208 | 0.050 |
Why?
| | Fingers | 1 | 2004 | 107 | 0.050 |
Why?
| | Probability | 1 | 2004 | 308 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 360 | 0.050 |
Why?
| | Vascular Patency | 1 | 2003 | 121 | 0.050 |
Why?
| | Receptors, Angiotensin | 1 | 2002 | 11 | 0.050 |
Why?
| | Equipment Failure | 1 | 2003 | 115 | 0.050 |
Why?
| | Triglycerides | 1 | 2005 | 520 | 0.050 |
Why?
| | Medical Records | 1 | 2003 | 192 | 0.040 |
Why?
| | Renin-Angiotensin System | 1 | 2002 | 80 | 0.040 |
Why?
| | Thrombolytic Therapy | 1 | 2003 | 164 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 528 | 0.040 |
Why?
| | Vasodilation | 1 | 2005 | 521 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2010 | 1420 | 0.040 |
Why?
| | Graft Survival | 1 | 2004 | 519 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1547 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2003 | 770 | 0.040 |
Why?
| | Behavior Therapy | 1 | 2004 | 296 | 0.040 |
Why?
| | Prospective Studies | 2 | 2004 | 8078 | 0.040 |
Why?
| | Counseling | 1 | 2004 | 401 | 0.040 |
Why?
| | Risk Assessment | 2 | 2015 | 3752 | 0.040 |
Why?
| | Graft Rejection | 1 | 2004 | 521 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2013 | 5428 | 0.040 |
Why?
| | Sex Factors | 1 | 2005 | 2110 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2013 | 17330 | 0.030 |
Why?
| | Polypharmacy | 1 | 2015 | 94 | 0.030 |
Why?
| | Ranolazine | 1 | 2013 | 23 | 0.030 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2014 | 71 | 0.020 |
Why?
| | Young Adult | 1 | 2010 | 14254 | 0.020 |
Why?
| | Time Factors | 1 | 2003 | 7134 | 0.020 |
Why?
| | Risk | 1 | 2014 | 923 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2011 | 75 | 0.020 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2011 | 116 | 0.020 |
Why?
| | Patient Selection | 1 | 2015 | 739 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1662 | 0.020 |
Why?
| | Digoxin | 1 | 2010 | 27 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2006 | 2064 | 0.020 |
Why?
| | Food-Drug Interactions | 1 | 2009 | 11 | 0.020 |
Why?
| | Signal Transduction | 1 | 2003 | 5224 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2028 | 0.020 |
Why?
| | Acetylcysteine | 1 | 2010 | 139 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 125 | 0.020 |
Why?
| | Animals | 1 | 2012 | 38101 | 0.020 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2014 | 549 | 0.020 |
Why?
| | Valsartan | 1 | 2006 | 32 | 0.020 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 38 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2014 | 1211 | 0.010 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 444 | 0.010 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2004 | 198 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1782 | 0.010 |
Why?
|
|
Packard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|